Literature DB >> 16863787

Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms.

Adam M Ostrow1, Hudson Freeze, Jack Rychik.   

Abstract

BACKGROUND: Protein-losing enteropathy (PLE) is an enigmatic disease with significant morbidity and mortality seen after the Fontan operation. The pathophysiology is poorly understood. The purpose of this study is to investigate the association between PLE after the Fontan operation and candidate pathophysiologic mechanisms of the disease by searching for abnormalities of the following: (1) mesenteric blood flow; (2) systemic inflammation; (3) neurohormonal activation; (4) protein glycosylation.
METHODS: A cross-sectional analysis of 62 patients after the Fontan operation was performed. Twenty-four hour stool sample was collected for alpha-1-antitrypsin (A1AT) clearance, to determine the presence of abnormal enteric protein loss (AEPL) defined as either an abnormal fecal A1AT clearance of greater than 27 mL/24 hours, or an abnormal fecal A1AT concentration of greater than 54 mg/dL. Subjects underwent ultrasonography of the mesenteric and celiac artery blood flow and blood draw for tumor necrosis factor-alpha (TNF-a), high sensitivity C reactive protein (CRP), brain natriuretic peptide (BNP), angiotensin II, coagulation factors protein S, protein C, and antithrombin III (AT III), and serum transferrin for determination of glycosylation defect.
RESULTS: Age at study was 10.9 +/- 3.4 years; 8.6 +/- 3.9 years after the Fontan operation. Seven subjects had AEPL. Mesenteric-to-celiac artery flow ratio was lower for the AEPL group, than for the non-AEPL group (p < 0.05). The TNF-a, CRP, BNP, and angiotensin II levels were elevated; however, there was no correlation with AEPL. Abnormalities in coagulation factors were present but did not correlate with AEPL. No glycosylation defects were identified.
CONCLUSIONS: Potential candidate mechanisms for elucidation of the pathophysiology of PLE include abnormal mesenteric vascular resistance and inflammation, conditions uniquely present after the Fontan operation. Targeted investigations of these parameters may provide clues as to the mechanism of onset of PLE after Fontan operation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863787     DOI: 10.1016/j.athoracsur.2006.02.048

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  27 in total

1.  Fontan-associated protein-losing enteropathy and plastic bronchitis.

Authors:  Kurt R Schumacher; Kathleen A Stringer; Janet E Donohue; Sunkyung Yu; Ashley Shaver; Regine L Caruthers; Brian J Zikmund-Fisher; Carlen Fifer; Caren Goldberg; Mark W Russell
Journal:  J Pediatr       Date:  2015-02-04       Impact factor: 4.406

2.  Early Impact of Fontan Operation on Enteric Protein Loss.

Authors:  Jyoti K Patel; Kathleen M Loomes; David J Goldberg; Laura Mercer-Rosa; Kathryn Dodds; Jack Rychik
Journal:  Ann Thorac Surg       Date:  2015-12-01       Impact factor: 4.330

Review 3.  The Lymphatic Circulation in Adaptations to the Fontan Circulation.

Authors:  Sabarinath Menon; Murthy Chennapragada; Shinya Ugaki; Gary F Sholler; Julian Ayer; David S Winlaw
Journal:  Pediatr Cardiol       Date:  2017-02-16       Impact factor: 1.655

4.  Successful combined intravenous and subcutaneous immunoglobulin treatment for intractable protein-losing enteropathy in a patient long after Fontan-type operation.

Authors:  Yoshiyuki Kagiyama; Shintaro Kishimoto; Hironaga Yoshimoto; Yoshiyuki Kudo; Kenji Gotoh; Kenji Suda
Journal:  J Cardiol Cases       Date:  2017-10-16

Review 5.  Report of the National Heart, Lung, and Blood Institute's Working Group on obesity and other cardiovascular risk factors in congenital heart disease.

Authors:  Victoria L Pemberton; Brian W McCrindle; Shari Barkin; Stephen R Daniels; Sarah E Barlow; Helen J Binns; Meryl S Cohen; Christina Economos; Myles S Faith; Samuel S Gidding; Caren S Goldberg; Rae-Ellen Kavey; Patricia Longmuir; Albert P Rocchini; Linda Van Horn; Jonathan R Kaltman
Journal:  Circulation       Date:  2010-03-09       Impact factor: 29.690

6.  Significance of circulating hepatocyte growth factor in protein-losing enteropathy after Fontan operation.

Authors:  Gi Beom Kim; Bo Sang Kwon; Eun Jung Bae; Chung Il Noh; Jung Yun Choi
Journal:  Pediatr Cardiol       Date:  2011-06-11       Impact factor: 1.655

7.  Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.

Authors:  Kurt R Schumacher; Michael Cools; Bryan H Goldstein; Viktoriya Ioffe-Dahan; Karen King; Diane Gaffney; Mark W Russell
Journal:  Pediatr Cardiol       Date:  2011-06-10       Impact factor: 1.655

8.  Prevalence of Subclinical Enteric Alpha-1-Antitrypsin Loss in Children with Univentricular Circulation Following Total Cavopulmonary Connection.

Authors:  Colm R Breatnach; Aoife Cleary; Terence Prendiville; Kathleen Crumlish; Helene Murchan; Colin J McMahon
Journal:  Pediatr Cardiol       Date:  2017-09-06       Impact factor: 1.655

9.  The Fontan pathway: What's down the road?

Authors:  Sachin Khambadkone
Journal:  Ann Pediatr Cardiol       Date:  2008-07

Review 10.  Clinical practice. Protein-losing enteropathy in children.

Authors:  Marjet J A M Braamskamp; Koert M Dolman; Merit M Tabbers
Journal:  Eur J Pediatr       Date:  2010-06-23       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.